NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis $19.02 +0.37 (+1.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$17.85▼$19.3650-Day Range$16.00▼$24.0552-Week Range$10.87▼$41.51Volume1.17 million shsAverage Volume1.88 million shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$31.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get NovoCure alerts: Email Address NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside67.6% Upside$31.88 Price TargetShort InterestBearish7.26% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.27Based on 19 Articles This WeekInsider TradingSelling Shares$23,030 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.59) to ($1.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.67 out of 5 starsMedical Sector266th out of 936 stocksSurgical & Medical Instruments Industry34th out of 101 stocks 3.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNovoCure has only been the subject of 4 research reports in the past 90 days.Read more about NovoCure's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.26% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in NovoCure has recently increased by 13.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 2.4 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for NovoCure this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows9 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,030.00 in company stock.Percentage Held by InsidersOnly 6.29% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NovoCure's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.59) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NovoCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesJuly 27 at 12:41 AM | fool.comNovoCure's Q2 Revenue Soars by 10.7%July 26 at 7:37 PM | seekingalpha.comNovoCure Limited: A Post Q2 AnalysisJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 26 at 2:53 AM | seekingalpha.comNovoCure Limited (NVCR) Q2 2024 Earnings Call TranscriptJuly 26 at 2:53 AM | markets.businessinsider.comMaintaining Hold on NovoCure Amid Moderate Growth and Anticipated Regulatory ApprovalsJuly 26 at 2:53 AM | msn.comNovoCure (NVCR) Q2 2024 Earnings Call TranscriptJuly 25 at 10:55 AM | finance.yahoo.comNovocure Reports Second Quarter 2024 Financial ResultsJuly 25 at 10:47 AM | seekingalpha.comNovoCure Limited 2024 Q2 - Results - Earnings Call PresentationJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 20, 2024 | sg.finance.yahoo.comNovoCure Limited (NVCR) latest stock news & headlines – Yahoo FinanceJuly 18, 2024 | americanbankingnews.comNovoCure (NVCR) Scheduled to Post Earnings on ThursdayJune 3, 2024 | businesswire.comMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free SurvivalMay 23, 2024 | businesswire.comTIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in GermanyMay 14, 2024 | investorplace.comDouble-Up Delights: 7 Stocks Poised to Soar 100% by 2025May 3, 2024 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | seekingalpha.comNovoCure Limited Q1 Earnings: Core Business AcceleratingMay 3, 2024 | fool.comNovoCure (NVCR) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comUnveiling 8 Analyst Insights On NovoCureSee More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today7/27/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,453Year FoundedN/APrice Target and Rating Average Stock Price Target$31.88 High Stock Price Target$51.00 Low Stock Price Target$17.00 Potential Upside/Downside+67.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-207,040,000.00 Net Margins-30.67% Pretax Margin-32.78% Return on Equity-45.37% Return on Assets-14.82% Debt Debt-to-Equity Ratio1.59 Current Ratio6.26 Quick Ratio5.99 Sales & Book Value Annual Sales$509.34 million Price / Sales4.02 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book5.61Miscellaneous Outstanding Shares107,610,000Free Float100,842,000Market Cap$2.05 billion OptionableOptionable Beta0.70 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. William F. Doyle (Age 62)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 58)CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 45)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 66)Chief Operating Officer Comp: $1.01MMr. Frank LeonardExecutive VP & President of Novocure OncologyProf. Yoram Palti M.D. (Age 86)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D. (Age 54)Chief Science Officer Ms. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel Mr. Michael Puri (Age 55)Chief Human Resources Officer More ExecutivesKey CompetitorsNevroNYSE:NVROPenumbraNYSE:PENBausch + LombNYSE:BLCOPROCEPT BioRoboticsNASDAQ:PRCTInari MedicalNASDAQ:NARIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 152,185 shares on 7/26/2024Ownership: 0.390%Legato Capital Management LLCBought 55,567 shares on 7/26/2024Ownership: 0.052%Baillie Gifford & Co.Sold 302,854 shares on 7/25/2024Ownership: 1.568%Fifth Third BancorpBought 2,500 shares on 7/22/2024Ownership: 0.002%Nisa Investment Advisors LLCBought 2,777 shares on 7/20/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions How have NVCR shares performed this year? NovoCure's stock was trading at $14.93 at the start of the year. Since then, NVCR stock has increased by 27.4% and is now trading at $19.02. View the best growth stocks for 2024 here. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, July, 25th. The medical equipment provider reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.09. The firm's revenue was up 19.3% compared to the same quarter last year. What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. Who are NovoCure's major shareholders? Top institutional shareholders of NovoCure include Baillie Gifford & Co. (1.57%), Bank of New York Mellon Corp (0.39%), SG Americas Securities LLC (0.13%) and Legato Capital Management LLC (0.05%). Insiders that own company stock include William F Doyle, Wilhelmus Cm Groenhuysen, W Anthony Vernon, Frank X Leonard, Pritesh Shah, Ashley Cordova, Uri Weinberg, Ely Benaim, Asaf Danziger, Jeryl L Hilleman, Todd Christopher Longsworth and Martin J Madden. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC) and Viper Energy (VNOM). This page (NASDAQ:NVCR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.